Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy | Zendy

Pat W. Whitworth | Zendy; Peter D. Beitsch | Zendy; Mary K. Murray | Zendy; Paul Richards | Zendy; Angela Mislowsky | Zendy; Carrie L. Dul | Zendy; James Pellicane | Zendy; Paul L. Baron | Zendy; Rakhshanda Layeequr Rahman | Zendy; Laura A. Lee | Zendy; Beth Dupree | Zendy; Pond R. Kelemen | Zendy; Andrew Y. Ashikari | Zendy; Raye Budway | Zendy; Cristina Lopez-Penalver | Zendy; William C. Dooley | Zendy; Shiyu Wang | Zendy; Patricia Dauer | Zendy; Andrea Menicucci | Zendy; Erin Yoder | Zendy; Christine Finn | Zendy; Lisa E. Blumencranz | Zendy; William Audeh | Zendy

Open Access

Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy

Author(s) -

Pat W. Whitworth,

Peter D. Beitsch,

Mary K. Murray,

Paul Richards,

Angela Mislowsky,

Carrie L. Dul,

James Pellicane,

Paul L. Baron,

Rakhshanda Layeequr Rahman,

Laura A. Lee,

Beth Dupree,

Pond R. Kelemen,

Andrew Y. Ashikari,

Raye Budway,

Cristina Lopez-Penalver,

William C. Dooley,

Shiyu Wang,

Patricia Dauer,

Andrea Menicucci,

Erin Yoder,

Christine Finn,

Lisa E. Blumencranz,

William Audeh

Publication year - 2022

Publication title -

jco precision oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.405

H-Index - 22

ISSN - 2473-4284

DOI - 10.1200/po.22.00197

Subject(s) - trastuzumab , medicine , oncology , breast cancer , pertuzumab , fluorescence in situ hybridization , neoadjuvant therapy , targeted therapy , stage (stratigraphy) , cancer , gene , biology , paleontology , biochemistry , chromosome

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research